The US-China split now runs through ownership, not molecules

To compete with Chinese biotechs, you have to run as fast as they do, which takes a bigger round and more risk, or build something Beijing won't let them sell.

China wins in drugs on time rather than on labour cost: teams run toxicology, manufacturing and trial preparation at once, share hospital data nationally, and do early discovery work for a third to half of what it costs elsewhere. Forty percent of the assets big pharma licensed last year came from Chinese companies.

Beijing's draft rules from 16 October keep Chinese platforms licensable but take away the sale, and Washington's COINS draft limits American equity stakes in Chinese biotech. The split now runs through ownership: pharma can rent a Chinese platform, but it cannot own one. So the question for a Western company is whether pharma will want to own it, the way it bought Juno, Dicerna and Translate Bio after licensing them first.